Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
2.220
-0.180 (-7.50%)
At close: Sep 18, 2026, 4:00 PM EDT
2.290
+0.070 (3.15%)
After-hours: Sep 18, 2026, 7:30 PM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 16 employees as of December 31, 2025. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$2,356,813
Market Cap
22.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2024 | 15 | 3 | 25.00% | 15 | 0 |
| Dec 31, 2023 | 12 | 1 | 9.09% | 12 | 0 |
| Dec 31, 2022 | 11 | 3 | 37.50% | 11 | 0 |
| Dec 31, 2021 | 8 | 0 | - | 6 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Evaxion | 46 |
| Lantern Pharma | 16 |
| Actuate Therapeutics | 12 |
| Tvardi Therapeutics | 12 |
| Psyence Biomedical | 12 |
| Cellectar Biosciences | 11 |
| Cocrystal Pharma | 10 |
ATOS News
- 6 weeks ago - Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PRNewsWire
- 6 weeks ago - Atossa Therapeutics Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Atossa Therapeutics Earnings release: Q2 2026 - Filings
- 7 weeks ago - Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer - PRNewsWire
- 2 months ago - Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers - PRNewsWire
- 3 months ago - Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds - PRNewsWire
- 3 months ago - Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds - PRNewsWire
- 3 months ago - Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PRNewsWire